8-K current report · filed Nov 9, 2026

Tango Therapeutics, Inc. (TNGX) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1TNGX overview

Short answer

Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Tango Therapeutics’ quarter ended September 30, 2026.

Tango Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Tango Therapeutics’ quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s operating results and financial condition update

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1/2 combination data showed 82% ORR and 88% nine-month PFS in 2L/3L pancreatic cancer
  • Phase 3 front-line MTAP-deleted pancreatic cancer study planned for 1H 2027, with ORR and PFS as primary endpoints
  • Cash, cash equivalents and marketable securities totaled $977.5M, supporting the current operating plan
  • Collaboration revenue fell to $0 from $53.8M year over year, reflecting completion of the Gilead collaboration
  • Nine-month net loss widened to $169.2M, or $1.08 per share, from $62.8M, or $0.57 per share

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tango Therapeutics, Inc. 8-K filings

Get the next TNGX 8-K as it lands

Follow TNGX for push alerts, or ask the research agent what this filing means.